Frequently asked questions

ProstateGuard is an at-home blood test kit that measures the Prostate Health Index (phi) and provides a report designed to help assess prostate cancer risk. It does not diagnose cancer and should be used alongside clinical evaluation.

Many men use phi as part of an evaluation for prostate cancer risk—often when PSA is in a borderline range and a biopsy decision is being considered. A licensed healthcare professional can help determine if it’s appropriate for you.

The Prostate Health Index (phi) blood test is FDA approved as an aid in distinguishing prostate cancer from benign prostatic conditions in appropriate patients. The Tasso+ device used for upper-arm collection is FDA 510(k)-cleared as a Class II lancet.

You’ll use a Tasso® upper-arm collection device. After prepping the site, you apply the device and press a button to begin collection. The sample is then sealed and shipped to the lab in the provided mailer.

Turnaround time can vary based on shipping and lab volume. You’ll receive an email or text notification when your report is ready.

A lower-risk result does not guarantee that cancer is absent. Some cancers may not be detected or may require different diagnostic approaches. Continue routine screening and follow your clinician’s guidance.

An elevated-risk result is not a diagnosis of cancer. Your clinician may recommend further evaluation such as imaging or biopsy. Any screening or risk assessment test can produce results that do not match final diagnosis.

No. ProstateGuard is intended to complement—not replace—clinician-recommended screening and diagnostic pathways.